Home
Companies
Catalysts
Deep Dives
C3 glomerulopathy
C3G · Immunology · 2 drugs · 2 indications
Competitive Landscape (2 drugs)
Drug
Company
Mechanism
Modality
Route
Stage
Fabhalta
NVS
Complement factor B inhibitor
Small molecule
Oral
APPROVED
Aspaveli
SOBI
C3 complement inhibitor
PEGylated peptide
SC
APPROVED
Indications (2)
C3G / IC-MPGN
Aspaveli
APPROVED
C3 glomerulopathy
Fabhalta
PHASE3
Upcoming Catalysts
Fabhalta - IgAN - Full Approval Data
CLINICAL
NVS
H2 2026
Data from Supabase · Updated 2026-03-24